# Brigitte C. Widemann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/brigitte-c-widemann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,635 |
| Field | Neurofibromatosis and Schwannoma Cases |
| h-index | 72 |
| i10-index | 218 |
| Last Known Institution | National Institutes of Health |
| OpenAlex ID | https://openalex.org/A5071679104 |
| ORCID iD | 0000-0002-9198-7175 |
| Works | 710 |

## Researcher papers

Showing 12 of 14.

- [Understanding and Managing Methotrexate Nephrotoxicity](https://scholariq.org/papers/understanding-and-managing-methotrexate-nephrotoxicity/)
- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas](https://scholariq.org/papers/activity-of-selumetinib-in-neurofibromatosis-type-1-related-plexiform/)
- [Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma](https://scholariq.org/papers/inhibition-of-b-cell-receptor-signaling-by-ibrutinib-in-primary-cns-lymphoma/)
- [Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview](https://scholariq.org/papers/histopathologic-evaluation-of-atypical-neurofibromatous-tumors-and-their/)
- [Low-Intensity Therapy in Adults with Burkitt's Lymphoma](https://scholariq.org/papers/low-intensity-therapy-in-adults-with-burkitt-s-lymphoma/)
- [MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors](https://scholariq.org/papers/mek-inhibition-exhibits-efficacy-in-human-and-mouse-neurofibromatosis-tumors/)
- [High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma](https://scholariq.org/papers/high-dose-methotrexate-induced-nephrotoxicity-in-patients-with-osteosarcoma/)
- [Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1](https://scholariq.org/papers/assessment-of-benign-tumor-burden-by-whole-body-mri-in-patients-with/)
- [Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance](https://scholariq.org/papers/consensus-guideline-for-use-of-glucarpidase-in-patients-with-high-dose/)
- [Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum](https://scholariq.org/papers/safety-and-efficacy-of-low-dose-sirolimus-in-the-pik3ca-related-overgrowth/)
- [NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas](https://scholariq.org/papers/nf106-a-neurofibromatosis-clinical-trials-consortium-phase-ii-trial-of-the-mek/)

## Researcher topics

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Childhood Cancer Survivors' Quality of Life](https://scholariq.org/topics/childhood-cancer-survivors-quality-of-life/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)

## Researcher university

- [National Institutes of Health](https://scholariq.org/institutions/national-institutes-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.